Raymonda Rastegar, MD
Cardiovascular Disease · New York, NYNPI 1609888403
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $219,873 of the $278,458 with a category attached, or 79.0%. Novo Nordisk accounts for 84.9% of it on its own, with 39 other manufacturers making up the rest. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 944 payments — averaging $294.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$236K
- Amarin Pharma, Inc.$19K
- Lexicon Pharmaceuticals, Inc.$4K
- Boehringer Ingelheim$2K
- AstraZeneca$2K
- Pfizer$2K
- plus $14K from 34 others
What the payments were for
- Consulting fees$8,9953%
- Speaking & faculty fees$219,87379%
- Travel & lodging$25,3459%
- Food & beverage$23,9659%
- Education$2800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$278,458 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 262 | $322,061 |
| OzempicSemaglutide | 224 | $249,446 |
| OpsumitMacitentan | 12 | $153,841 |
| JardianceEmpagliflozin | 111 | $123,665 |
| Repatha SureclickEvolocumab | 126 | $98,211 |
| EntrestoSacubitril/Valsartan | 71 | $96,628 |
| XareltoRivaroxaban | 55 | $74,018 |
| Praluent PenAlirocumab | 91 | $61,550 |
| RybelsusSemaglutide | 31 | $40,164 |
| MultaqDronedarone Hcl | 21 | $38,951 |
| FarxigaDapagliflozin Propanediol | 39 | $35,556 |
| WegovySemaglutide | 22 | $29,900 |
| LivaloPitavastatin Calcium | 41 | $26,969 |
| VascepaIcosapent Ethyl | 41 | $18,623 |
| InpefaSotagliflozin | 11 | $16,285 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,651 | $322,061262 claims |
| Novo NordiskOzempic, Rybelsus, Wegovy | $236,435 | $319,509277 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $764 | $153,84112 claims |
| Boehringer IngelheimJardiance | $2,353 | $123,665111 claims |
| NovartisEntresto | $697 | $96,62871 claims |
| Johnson & JohnsonXarelto | $1,143 | $74,01855 claims |
| Sanofi-aventis U.S. LLCMultaq | $1,474 | $38,95121 claims |
| AstraZenecaFarxiga | $1,782 | $35,55639 claims |
| Kowa Pharmaceuticals America, Inc.Livalo, Bystolic | $730 | $34,25061 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $3,535 | $16,28511 claims |
| Esperion Therapeutics, Inc.Nexletol | $1,156 | $15,92035 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $236 | $11,73124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in New York
- Roger HajjarNew York$5.2M
- Gregg StoneNew York$2M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Megha PrasadNew York$813K
- Eyal HerzogNew York$645K
- Nisha JhalaniNew York$443K
- Roxana MehranNew York$432K
- Howard WeintraubNew York$328K
- Anuradha Lala-TrindadeNew York$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.